Endoscopic ultrasound-guided thrombin injection, a management approach for visceral artery pseudoaneurysms

Authors
Sudhir Maharshi, Shyam Sunder Sharma, Deepak Sharma, Bharat Sapra, Sandeep Nijhawan

Institution
Department of Gastroenterology, SMS Hospital, Jaipur, India

submitted 20.8.2019
accepted after revision 28.10.2019

Bibliography

Corresponding author
Shyam Sunder Sharma, DM, Department of Gastroenterology, Room No. 303, Gastro Lab, SMS Medical College and Hospitals, Jaipur 302004, India Fax: +91-141-2564222 shyamsharma4@rediffmail.com

ABSTRACT
Background and study aims Pseudoaneurysms are usually associated with high rates of morbidity and mortality. There are limited data in the literature on endoscopic ultrasound (EUS)-guided thrombin injection for pseudoaneurysms. The aim of this study is to assess the efficacy and safety of EUS-guided thrombin injection for pseudoaneurysms.

Patients and methods This prospective study was conducted in our department between January and December 2018. All patients with symptomatic visceral artery pseudoaneurysms, who were unable to undergo angioembolization, were enrolled consecutively. Data related to demographics, laboratory parameters, radiological imaging, pseudoaneurysms, and endotherapy were analyzed.

Results Eight patients with median age 34 years (27–58 years), all men, were studied. The vessel involved was the splenic artery in 5 patients (62.5%), the left hepatic artery in 2 (25%), and the gastroduodenal artery in 1 patient (12.5%). The median size of the pseudoaneurysms was 2.9 cm × 2.6 cm (range, 1.8 × 1.9–4 × 5 cm). The median thrombin requirement was 400 IU (range, 200–500 IU) for loss of Doppler flow signals. EUS after 3 months showed obliterated pseudoaneurysms in 7 patients (87.5%), while recurrence was observed in 1 patient (12.5%) after 6 weeks.

Conclusions EUS-guided thrombin injection may be a new option for the management of pseudoaneurysms.

Introduction
Visceral artery pseudoaneurysm is a common complication of pancreatitis seen in 10% of patients with chronic pancreatitis and with a risk of rupture as high as 50% and with a rate of mortality after rupture of 15–40% [1,2]. Therefore, visceral artery pseudoaneurysm should be promptly diagnosed and treated. Digital subtraction angiography with subsequent coil embolization is the standard treatment to occlude the pseudoaneurysm [3].

Indication for endoscopic ultrasound (EUS)-guided thrombin injection
Occasionally, coil embolization is not possible for various reasons such as short neck of the pseudoaneurysm, inaccessible vascular territory, or angiographically occult pseudoaneurysm, which can be seen on ultrasound and computed tomography (CT) of the abdomen. In these cases, ultrasound or CT-guided percutaneous thrombin injection can be performed [4,5]. EUS-guided thrombin injection is another option in these patients, especially when pseudoaneurysm localization is difficult on transabdominal ultrasound, thus we can avoid surgery and morbidity. This procedure is simple, minimally invasive, effective, and cheaper than angioembolization.
Methods

Endoscopic ultrasound with a curved linear array transducer in conjunction with a light source was used for this procedure. An intravenous antibiotic was administered 30 minutes before the procedure. The pseudoaneurysm was identified, and the shortest path without any intervening vessel was chosen. Sterile lyophilized human thrombin was used, reconstituted with 1 mL of calcium chloride and 4 mL of distilled water to a total of 5 mL. An EchoTip Ultra 22-gauge EUS needle (Cook Medical, Bloomington, Indiana, United States) was used to puncture the pseudoaneurysm, under EUS guidance. After puncture, the reconstituted thrombin was injected in aliquots of 1 mL until the pseudoaneurysm became echogenic. Further details of the procedure are given later in Materials and methods [3, 6].

Outcome

There is limited data on EUS-guided thrombin injection in visceral artery pseudoaneurysms. Initial case reports revealed successful use of EUS-guided thrombin injection in the management of visceral artery pseudoaneurysms [7–12]. A case series on three patients with visceral artery pseudoaneurysms due to pancreatitis revealed complete thrombosis of the pseudoaneurysm and on short follow-up of 1 month, none of the patients had recurrence of symptoms [3]. Another small case series with short follow-up showed similar results [6]. EUS-guided thrombin injection has also been used successfully along with coil in a bleeding gastroduodenal artery pseudoaneurysm [13]. A recently published case report showed that EUS-guided thrombin can also be used in cystic artery pseudoaneurysm [11]. So the limited available literature favors the use of EUS-guided thrombin injection in the management of visceral artery pseudoaneurysms without significant side effects, although long-term follow-up data are not available. Various vascular pathologies and the proximity of the vascular structure to the gastrointestinal tract wall have prompted EUS experts to perform various EUS-guided vascular procedures. High resolution, proximity of vascular pathology to the gastrointestinal tract wall, and real-time guidance offer precise delivery of the intervention. To date, various EUS-guided vascular therapies have been identified such as EUS-guided management of nonvariceal gastrointestinal bleeding, variceal bleeding, pseudoaneurysm, embolization of the portal venous system, and creation of portosystemic shunts [14].

Visceral artery pseudoaneurysms include aneurysms of the celiac, superior, or inferior mesenteric arteries and their branches. Pseudoaneurysms have a high risk of rupture with life threatening consequences [15]. With reported incidences of 0.1–0.2%, visceral artery aneurysms and pseudoaneurysms are relatively rare, but the true incidence is not known since many are asymptomatic [16]. Pseudoaneurysms usually occur after vascular injuries or erosions such as in trauma or inflammation. The increasing use of instrumentation and advanced imaging technologies has led to the increased incidental detection of asymptomatic pseudoaneurysms [17, 18]. The established procedure to manage pseudoaneurysms is angiography with coil embolization but, due to non-visualization with angiography or inaccessibility (small caliber vessels or short neck of pseudoaneurysm), this technique is not possible in some cases.

Pseudoaneurysms are reported in 10–21% of patients with chronic pancreatitis, and the splenic artery is most commonly affected [19]. EUS-guided thrombin injection is another possible approach, especially in patients where the established management procedure is not possible. High resolution and real-time guidance by EUS offer an attractive access route and precise delivery of the intervention [14]. Thrombin is the principal enzyme of hemostasis. It catalyzes the conversion of fibrinogen to fibrin and activates procoagulant factors V, VIII, XI, and XIII. It also activates platelets and forms a solid clot. Thrombin activated with calcium chloride causes the immediate formation of a clot which leads to obliteration of the pseudoaneurysm [20]. There are limited data on EUS-guided thrombin injection for treatment of pseudoaneurysms. The aim of this study is to assess the efficacy and safety of EUS-guided thrombin injection in pseudoaneurysms.

Materials and methods

At SMS Hospital, Jaipur, India between January and December 2018, prospective data were collected from consecutive patients in all age groups with symptomatic visceral artery pseudoaneurysms, and who were unable to undergo coil embolization. The diagnosis of pseudoaneurysm was made on the basis of clinical features, radiological evidence, and endosonographic findings. Each patient underwent detailed clinical evaluation and laboratory investigations including hemogram, prothrombin time, and liver and kidney function tests. A computed tomography (CT) scan along with angiography of the abdomen were performed to look for pseudoaneurysms and any intraabdominal shunts. All patients were admitted and started on standard treatment including intravenous fluid, blood products, and antibiotics. The upper gastrointestinal endoscopy was carried out using a forward viewing endoscope (Olympus GIF-1TQ 160, Tokyo, Japan). After initial stabilization, patients underwent detailed EUS examination and thrombin was injected in the pseudoaneurysm. The required amount of thrombin, procedure time, and any complications were observed. Follow-up EUS was performed after 72 hours, 1 month, and 3 months to look for recanalization. Follow-up CT scan of the abdomen was also performed after 1 month to identify any side effects distant to the target. The study protocol was approved by the institutional ethics committee. Informed written consent was obtained from each patient before the procedure and the research was carried out in accordance with the Helsinki Declaration.

Technique of endoscopic ultrasound-guided thrombin injection

Endoscopic ultrasound was performed using a curved linear array transducer (Olympus-GFUCT-180) in conjunction with an EVIS EXERA CLV-180 light source (Olympus Medical System Corp., Tokyo, Japan). An intravenous antibiotic (2 g of ceftriaxone) was administered 30 minutes before the procedure. The procedures were performed under conscious sedation (3 mg in-
travenous midazolam). The pseudoaneurysm was identified, and the shortest path without any intervening vessel was chosen. Characteristics of the pseudoaneurysm such as vessel involved, size, neck size, and relationship to adjacent structures were assessed. To-and-fro flow of blood in the pseudoaneurysm suggestive of the yin-yang sign was confirmed with color Doppler (▶Fig. 1b,d,f). Sterile lyophilized human thrombin was used, made from pooled human blood plasma. Just before the procedure, thrombin was reconstituted with 1mL of calcium chloride and 4mL of distilled water to a total of 5mL. Thus, each 1mL of reconstituted solution contained 100IU of thrombin. An EchoTip Ultra 22-gauge EUS needle (Cook Medical, Bloomington, Indiana, United States) was used to puncture the pseudoaneurysm, under EUS guidance (▶Fig. 2a). After puncture, the reconstituted thrombin was injected in aliquots of 1mL until the pseudoaneurysm became echogenic. The thrombin was injected into the sac but away from the neck to reduce the risk of distant thromboembolism. The technical success of the procedure was confirmed with loss of Doppler signal inside the pseudoaneurysm sac (▶Fig. 2b) and the needle was removed. A gastroenterologist, who had sufficient experience (>100 EUS-guided therapeutic procedures), performed these procedures.

**Statistical analysis**

Statistical analysis was performed using IBM SPSS Statistics for Windows, trial version 23.0 (IBM Corp, Armonk, NY, United States). Data were expressed as absolute numbers with percentages for categorical variables. Continuous data were expressed as median with interquartile range as appropriate. Data related to demography, laboratory parameters, radiological imaging, pseudoaneurysm, and endotherapy were analyzed.

**Results**

In total, eight patients underwent EUS-guided thrombin injection for pseudoaneurysms during the study period. Baseline demographic, clinical, and laboratory parameters are shown in ▶Table 1. Six patients (75%) had chronic pancreatitis. The etiology of chronic pancreatitis was alcohol abuse in all six patients. None of the patients had a history of trauma, surgery or any vascular intervention in the past. Two patients (25%) with left hepatic artery pseudoaneurysms had evidence of hemobilia.
on side view endoscopy. CT of the abdomen revealed that 5
patients (62.5 %) had pseudoaneurysm of the splenic artery, 2
(25 %) had pseudoaneurysm of the left hepatic artery, and 1 pa-
tient (12.5 %) had gastroduodenal artery pseudoaneurysm
▶ Fig. 1a, c, e). None of the patients had intraabdominal
shunts. Procedural and outcome de-
tails of individual patients
are shown in ▶ Table 2. One patient with left hepatic artery
pseudoaneurysm also had acute cholangitis and required en-
doscopic retrograde cholangiopancreatography (ERCP) with
stenting of the common bile duct (CBD) after thrombin injec-
tion and was treated with intravenous antibiotics (Ceftriaxone).
In three of our study patients, coil embolization was refused by
the cardiologist and radiologist because of non-visualization or
inaccessibility of the feeding vessel, and five could not afford to
undergo coil angioembolization, as this procedure is very ex-
pensive compared to EUS-guided thrombin injection.

Description of lesion
The median pseudoaneurysm sac size was 2.9 cm × 2.6 cm
(1.8 × 1.9–4 × 5 cm). The median neck length of the pseudo-
aneurysm from the vessel of origin was 3.1 mm (2.8–3.5 mm)
and it was narrower than a point source at its origin. Two pa-
tients had pancreatic pseudocysts and three had walled off ne-
crosis.

Technical success
With EUS-guided direct and precise thrombin injection, we
were able to achieve 100 % technical success. The median
amount of injected thrombin was 400 IU (200–500 IU) which
depended upon the size of the pseudoaneurysm sac. The medi-
ann procedure time was 11 minutes (8–15 minutes). After the
procedure, patients were monitored closely for hemodynamic
stability. Two patients developed post-procedural pain in the
abdomen, which required intravenous analgesics. None of the
patients had a rupture of the pseudoaneurysm, bleeding or dis-
tal arterial thromboembolism. After 72 hours and 4 weeks, re-
peat EUS showed obliterated pseudoaneurysm in all patients
▶ Fig. 2c, d).

Clinical success
Clinical success of the procedure was observed in 7 patients
(87.5 %) after a median sustained follow-up of 6 months (1–9
months), and 1 patient (12.5 %) had recanalization after 6
weeks, as he presented with hematemesis which required re-
peat thrombin injection. Follow-up CT scans of the abdomen,
performed after 1 month to look for any side effect distant to
the target, were normal in all patients. These data indicate
that the procedure was very successful in all patients.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (range), years</td>
<td>34 (27–58)</td>
</tr>
<tr>
<td>Sex, male/female, n</td>
<td>8:0</td>
</tr>
<tr>
<td>Smoker, n (%)</td>
<td>8/8 (100 %)</td>
</tr>
<tr>
<td>Chronic alcohol consumption, n (%)</td>
<td>6/8 (75 %)</td>
</tr>
<tr>
<td>Presenting symptoms, n (%)</td>
<td></td>
</tr>
<tr>
<td>• Pain abdomen</td>
<td>8/8 (100 %)</td>
</tr>
<tr>
<td>• Melena</td>
<td>8/8 (100 %)</td>
</tr>
<tr>
<td>• Hematemesis</td>
<td>6/8 (75 %)</td>
</tr>
<tr>
<td>• Fever</td>
<td>2/8 (25 %)</td>
</tr>
<tr>
<td>• Jaundice</td>
<td>2/8 (25 %)</td>
</tr>
</tbody>
</table>

Biochemical parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin, median (range), g/dL</td>
<td>5.8 (4.1–8.8)</td>
</tr>
<tr>
<td>TLC, median (range), 10³/mL</td>
<td>8.6 (6.35–15.12)</td>
</tr>
<tr>
<td>Platelet count, median (range), 10³/mL</td>
<td>1.85 (1.54–6.95)</td>
</tr>
<tr>
<td>PT-INR</td>
<td>1.2 (0.9–1.52)</td>
</tr>
<tr>
<td>Blood transfusion requirement, median (range), units</td>
<td>3 (2–5)</td>
</tr>
<tr>
<td>Follow-up, median (range), months</td>
<td>3 (1–6)</td>
</tr>
<tr>
<td>Thrombin required, median (range), IU</td>
<td>400 (200–500)</td>
</tr>
</tbody>
</table>

PT-INR, prothrombin time expressed as international normalized ratio; TLC, total lymphocyte count.
Discussion

Our study presents a novel management approach using EUS-guided thrombin injection in visceral artery pseudoaneurysms. This treatment was successful in all eight patients in the study. Injection of coil and glue has also been described in the literature for management of visceral artery pseudoaneurysms. A small case series showed the efficacy of EUS-guided transgastric injection of coil and glue in patients with splenic artery pseudoaneurysms. In that study, six patients with splenic artery pseudoaneurysm, who failed angiographic embolization, underwent EUS-guided cyanoacrylate glue and coil injection in pseudoaneurysms. All patients had complete occlusion of the pseudoaneurysms at week 4 and 12 without any complications [21]. Another study proved the efficacy of ultrasound-guided tissue glue injection for the treatment of femoral artery pseudoaneurysms [22]. Initial studies on percutaneous ultrasound-guided thrombin injection concluded that it is a quick, effective, and safe treatment for pseudoaneurysms [18, 19]. A few initial case reports showed the successful use of EUS-guided thrombin injection in the management of visceral artery pseudoaneurysms [7–12]. Another small case series described the successful use of EUS-guided human thrombin with no recurrence on short follow-up [6].

To date, no large study has been published on EUS-guided thrombin injection in pseudoaneurysms. EUS-guided interventions are minimally invasive, can be performed under conscious sedation, and decrease procedure time and hospital stay. They are also simple, effective, and cheaper than angioembolization. Human thrombin does not have the risk of immunological reaction and contamination with prions which was observed in a few cases with bovine thrombin [23]. Thrombin injection can cause complications in the form of downstream embolization into the arterial system and, although rare, this has been well documented [24]. This risk is high if the neck is less than 3 mm in length or wider than a point source at its origin. In our study, the median neck length was 3.1 mm (2.8–3.5 mm) and we injected thrombin into the aneurysmal sac, away from the neck. None of our patients developed distal arterial embolization.

A limitation of this study was that it was a small case series with short duration follow-up. Larger studies with long-term follow-up are needed to further prove the efficacy and safety of the procedure.

In conclusion, EUS-guided thrombin injection provides an alternative for management of visceral artery pseudoaneurysms. It is most useful in patients where endovascular coil embolization is not possible or in patients having a high surgical risk but can be used in all patients as it is simple, minimally invasive, effective and cheaper than angioembolization.

Competing interests

The authors declare that they have no conflict of interest.

References


Table 2: Clinical features, procedural details, and outcomes of the study patients.

<table>
<thead>
<tr>
<th>Serial number</th>
<th>Age, years</th>
<th>Etiology</th>
<th>Vessel involved</th>
<th>Pseudoaneurysm size, cm</th>
<th>Pseudoaneurysm neck length, mm</th>
<th>Thrombin required, IU</th>
<th>Procedure time, minutes</th>
<th>Outcome (after 6 months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>35</td>
<td>Chronic pancreatitis</td>
<td>Splenic artery</td>
<td>4 × 5</td>
<td>3.3</td>
<td>500</td>
<td>12</td>
<td>Obliterated</td>
</tr>
<tr>
<td>2</td>
<td>27</td>
<td>Chronic pancreatitis</td>
<td>Splenic artery</td>
<td>4 × 4</td>
<td>2.8</td>
<td>400</td>
<td>11</td>
<td>Obliterated</td>
</tr>
<tr>
<td>3</td>
<td>43</td>
<td>Chronic pancreatitis</td>
<td>Splenic artery</td>
<td>2.9 × 2.6</td>
<td>3.1</td>
<td>300</td>
<td>11</td>
<td>Obliterated</td>
</tr>
<tr>
<td>4</td>
<td>55</td>
<td>Chronic pancreatitis</td>
<td>Splenic artery</td>
<td>1.8 × 1.9</td>
<td>3.1</td>
<td>200</td>
<td>8</td>
<td>Obliterated</td>
</tr>
<tr>
<td>5</td>
<td>30</td>
<td>Idiopathic</td>
<td>Left hepatic artery</td>
<td>2 × 2</td>
<td>3.1</td>
<td>400</td>
<td>10</td>
<td>Obliterated</td>
</tr>
<tr>
<td>6</td>
<td>31</td>
<td>Idiopathic</td>
<td>Left hepatic artery</td>
<td>2.3 × 2.2</td>
<td>2.8</td>
<td>400</td>
<td>15</td>
<td>Obliterated</td>
</tr>
<tr>
<td>7</td>
<td>58</td>
<td>Chronic pancreatitis</td>
<td>Gastroduodenal artery</td>
<td>4 × 5</td>
<td>2.9</td>
<td>500</td>
<td>13</td>
<td>Recanalized. Repeat procedure required after 6 weeks</td>
</tr>
<tr>
<td>8</td>
<td>33</td>
<td>Chronic pancreatitis</td>
<td>Splenic artery</td>
<td>2.9 × 2.6</td>
<td>3.5</td>
<td>400</td>
<td>10</td>
<td>Obliterated</td>
</tr>
</tbody>
</table>


